Monkeypox vaccine safety under the microscope in congo study
NCT ID NCT05734508
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This completed study monitored the safety of the MVA-BN (Jynneos) vaccine in 500 adults at high risk for monkeypox in the Democratic Republic of the Congo. Participants received two doses of the vaccine and were followed for up to 28 days after their last dose. The main goal was to track any serious or minor side effects that occurred shortly after vaccination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut National de Rescherche Biomédicale (INRB)
Kinshasa, Democratic Republic of the Congo
-
L'Hôpital Général de Référence de Kole
Kole, Democratic Republic of the Congo
-
L'Hôpital Général de Référence de Tunda
Tunda, Democratic Republic of the Congo
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MVA-BN (Jynneos) vaccine
What this could lead to
If the vaccine is shown to be safe, it could support its use to protect people at high risk for monkeypox.
What could go wrong
This study only looked at safety, not how well the vaccine prevents infection. It was also small and limited to a specific group of adults.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.